An impedimetric micro-immunosensing assay to detect Alzheimer's disease biomarker: Aβ40

A miniaturized biosensing platform, based on monoclonal amyloid-beta antibodies (mAβab) that were immobilized on a disc-shaped platinum/iridium (Pt/Ir) microelectrode surface coupled with an impedimetric signal transducer, was developed for the label-free and sensitive detection of amyloid-beta pept...

Full description

Bibliographic Details
Published in:Analytical Biochemistry
Main Author: Zakaria N.; Ramli M.Z.; Ramasamy K.; Meng L.S.; Yean C.Y.; Banga Singh K.K.; Zain Z.M.; Low K.-F.
Format: Article
Language:English
Published: Academic Press Inc. 2018
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048000256&doi=10.1016%2fj.ab.2018.05.031&partnerID=40&md5=3caf21d7e5573d21b1db27bf0a170478
id 2-s2.0-85048000256
spelling 2-s2.0-85048000256
Zakaria N.; Ramli M.Z.; Ramasamy K.; Meng L.S.; Yean C.Y.; Banga Singh K.K.; Zain Z.M.; Low K.-F.
An impedimetric micro-immunosensing assay to detect Alzheimer's disease biomarker: Aβ40
2018
Analytical Biochemistry
555

10.1016/j.ab.2018.05.031
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048000256&doi=10.1016%2fj.ab.2018.05.031&partnerID=40&md5=3caf21d7e5573d21b1db27bf0a170478
A miniaturized biosensing platform, based on monoclonal amyloid-beta antibodies (mAβab) that were immobilized on a disc-shaped platinum/iridium (Pt/Ir) microelectrode surface coupled with an impedimetric signal transducer, was developed for the label-free and sensitive detection of amyloid-beta peptide fragment 1–40 (Aβ40); a reliable biomarker for early diagnosis of Alzheimer's disease (AD). A Pt/Ir microelectrode was electropolymerized with poly (ortho-phenylenediamine), a conducting free amine-containing aromatic polymer; followed by crosslinking with glutaraldehyde for subsequent coupling of mAβab on the microelectrode surface. This modification strategy efficiently improved the impedimetric detection performance of Aβ40 in terms of charge transfer resistance (∼400-fold difference) and normalized impedance magnitude percentage change (∼40% increase) compared with a passive adsorption-based immobilization method. The sensitivity of the micro-immunosensing assay was found to be 1056 kΩ/(pg/mL)/cm2 and the limit of detection was found to be 4.81 pg/mL with a dynamic range of 1−104 pg/mL (R2 = 0.9932). The overall precision of the assay, as measured by relative standard deviation, ranged from 0.84 to 5.15%, demonstrating its reliability and accuracy; while in respect to assay durability and stability, the immobilized mAβab were able to maintain 80% of their binding activity to Aβ40 after incubation for 48 h at ambient temperature (25 °C). To validate the practical applicability, the assay was tested using brain tissue lysates prepared from AD-induced rats. Results indicate that the proposed impedimetric micro-immunosensing platform is highly versatile and adaptable for the quantitative detection of other disease-related biomarkers. © 2018 Elsevier Inc.
Academic Press Inc.
00032697
English
Article

author Zakaria N.; Ramli M.Z.; Ramasamy K.; Meng L.S.; Yean C.Y.; Banga Singh K.K.; Zain Z.M.; Low K.-F.
spellingShingle Zakaria N.; Ramli M.Z.; Ramasamy K.; Meng L.S.; Yean C.Y.; Banga Singh K.K.; Zain Z.M.; Low K.-F.
An impedimetric micro-immunosensing assay to detect Alzheimer's disease biomarker: Aβ40
author_facet Zakaria N.; Ramli M.Z.; Ramasamy K.; Meng L.S.; Yean C.Y.; Banga Singh K.K.; Zain Z.M.; Low K.-F.
author_sort Zakaria N.; Ramli M.Z.; Ramasamy K.; Meng L.S.; Yean C.Y.; Banga Singh K.K.; Zain Z.M.; Low K.-F.
title An impedimetric micro-immunosensing assay to detect Alzheimer's disease biomarker: Aβ40
title_short An impedimetric micro-immunosensing assay to detect Alzheimer's disease biomarker: Aβ40
title_full An impedimetric micro-immunosensing assay to detect Alzheimer's disease biomarker: Aβ40
title_fullStr An impedimetric micro-immunosensing assay to detect Alzheimer's disease biomarker: Aβ40
title_full_unstemmed An impedimetric micro-immunosensing assay to detect Alzheimer's disease biomarker: Aβ40
title_sort An impedimetric micro-immunosensing assay to detect Alzheimer's disease biomarker: Aβ40
publishDate 2018
container_title Analytical Biochemistry
container_volume 555
container_issue
doi_str_mv 10.1016/j.ab.2018.05.031
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048000256&doi=10.1016%2fj.ab.2018.05.031&partnerID=40&md5=3caf21d7e5573d21b1db27bf0a170478
description A miniaturized biosensing platform, based on monoclonal amyloid-beta antibodies (mAβab) that were immobilized on a disc-shaped platinum/iridium (Pt/Ir) microelectrode surface coupled with an impedimetric signal transducer, was developed for the label-free and sensitive detection of amyloid-beta peptide fragment 1–40 (Aβ40); a reliable biomarker for early diagnosis of Alzheimer's disease (AD). A Pt/Ir microelectrode was electropolymerized with poly (ortho-phenylenediamine), a conducting free amine-containing aromatic polymer; followed by crosslinking with glutaraldehyde for subsequent coupling of mAβab on the microelectrode surface. This modification strategy efficiently improved the impedimetric detection performance of Aβ40 in terms of charge transfer resistance (∼400-fold difference) and normalized impedance magnitude percentage change (∼40% increase) compared with a passive adsorption-based immobilization method. The sensitivity of the micro-immunosensing assay was found to be 1056 kΩ/(pg/mL)/cm2 and the limit of detection was found to be 4.81 pg/mL with a dynamic range of 1−104 pg/mL (R2 = 0.9932). The overall precision of the assay, as measured by relative standard deviation, ranged from 0.84 to 5.15%, demonstrating its reliability and accuracy; while in respect to assay durability and stability, the immobilized mAβab were able to maintain 80% of their binding activity to Aβ40 after incubation for 48 h at ambient temperature (25 °C). To validate the practical applicability, the assay was tested using brain tissue lysates prepared from AD-induced rats. Results indicate that the proposed impedimetric micro-immunosensing platform is highly versatile and adaptable for the quantitative detection of other disease-related biomarkers. © 2018 Elsevier Inc.
publisher Academic Press Inc.
issn 00032697
language English
format Article
accesstype
record_format scopus
collection Scopus
_version_ 1814778507925913600